

Filgotinib and our commercial ambition

IR webcast | 16 December 2020

Galápagos
Pioneering for patients



Disclaimer

This presentation contains forward-looking statements, including (without limitation) statements concerning the opportunity for use of filgotinib for any indication, the timing of transition of commercialization and other activities, the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, the amount and timing of potential future milestone, development costs or other payments by Gilead, statements relating to interactions with regulatory authorities, the potential approval process for filgotinib and statements relating to the build-up of our commercial organization, and our strategy, business plans and focus, the expected timing, design and readouts of ongoing and planned clinical trials, and expectations regarding the commercial potential of our product candidates.

When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "possible," "predict," "objective," "should," "eligible" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons), reliance on third parties (including Galapagos' collaboration partner Gilead) and estimating the commercial potential of its product candidates.

A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission ("SEC") filing and reports, including Galapagos' most recent Form 20-F and subsequent filings with the SEC. Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements.

Except for filgotinib's approval for the treatment of rheumatoid arthritis by the European Commission and Japanese Ministry of Health, Labour and Welfare, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority and they are not yet approved for any use outside of clinical trials.

All statements herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change in future development with respect thereto, any future results, or any change in events, conditions and/or circumstances, on which any statement is based, unless specifically required by law or regulation.

Under no circumstances may any copy of this presentation, if obtained, be retained, copied, or transmitted.



Outcomes FDA discussion

No path forward for 200mg in RA

- GILD decided not to move forward with RA in the U.S.
- Insufficient opportunity now in PsA, AS & uveitis

MANTA/RA-y: up to 52 weeks follow-up required

- for any patients who do not recover fully by week 26 in H1 '21

IBD opportunity in US remains

- Positive Ph3 read-out in UC
- CD trial continues with data expected in H1 '22



New agreement for filgotinib



- GLPG responsible for all commercial activities for all indications in Europe
- Transition to GLPG commercial organization in Europe by end '21



- 50/50 P&L share for European commercialization until end '21
- All commercial economics to GLPG as of 1 Jan '22, subject to royalty 8% - 15% starting in 2024
- No more EU milestones to GLPG
- GILD to pay GLPG €160M



- GILD retains commercial rights ex-Europe
- Milestones & royalties to GLPG (20-30%) still applicable outside Europe

Broader R&D collaboration not impacted



Realizing our commercial vision

Value creation


**Acceleration
commercial
presence
across Europe**

**Preparation for
future launch
opportunities**

**Alignment with
overall R&D
collaboration
with Gilead**



EU5 inflammation market today*



Ambition:
≈€0.5B peak sales

8-12% market share for Jyseleca

RA: rheumatoid arthritis; CD: Crohn's disease; UC: ulcerative colitis

Source: IQVIA Analytic Link (MAT to Q2 2020) – est value by disease at ex mfr list prices. All biologics and tsDMARDs.

** U5 inflammation market accounts for approximately 68% of total EU market*

Jyseleca in RA



Filgotinib is approved for RA in the EU and Japan and not approved for use in any other indication nor any other region.

See the European Summary of Product Characteristics (SmPC) for Jyseleca, which includes contraindications and special warnings and precautions, available at www.ema.europa.eu.



Transition path


Market size

≈10% No change to Belgium & NL

≈70% EU5: Transfer of full business asap in '21

≈15% Alpine, Nordics & Ireland: transfer by YE '21

≈5% Rest of Europe: rights to GLPG



Transition to full European coverage by end 2021



Filgotinib timeline

